Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial

Scott R Garrison, Michael R Kolber, G Michael Allan, Jeffrey Bakal, Lee Green, Alexander Singer, Darryl R Trueman, Finlay A McAlister, Raj S Padwal, Michael D Hill, Braden Manns, Kimberlyn McGrail, Braden O'Neill, Michelle Greiver, Liesbeth S Froentjes, Donna P Manca, Dee Mangin, Sabrina T Wong, Cathy MacLean, Jessica Em Kirkwood, Rita McCracken, James P McCormack, Colleen Norris, Tina Korownyk, Scott R Garrison, Michael R Kolber, G Michael Allan, Jeffrey Bakal, Lee Green, Alexander Singer, Darryl R Trueman, Finlay A McAlister, Raj S Padwal, Michael D Hill, Braden Manns, Kimberlyn McGrail, Braden O'Neill, Michelle Greiver, Liesbeth S Froentjes, Donna P Manca, Dee Mangin, Sabrina T Wong, Cathy MacLean, Jessica Em Kirkwood, Rita McCracken, James P McCormack, Colleen Norris, Tina Korownyk

Abstract

Introduction: Sleep-time blood pressure correlates more strongly with adverse cardiovascular events than does daytime blood pressure. The BedMed trial evaluates whether bedtime antihypertensive administration, as compared with conventional morning use, reduces major adverse cardiovascular events. METHODS AND ANALYSIS: DesignProspective randomised, open-label, blinded end-point trial.ParticipantsHypertensive primary care patients using blood pressure lowering medication and free from glaucoma.SettingCommunity primary care providers in 5 Canadian provinces (British Columbia, Alberta, Saskatchewan, Manitoba and Ontario) are mailing invitations to their eligible patients. Social media campaigns (Google, Facebook) are additionally running in the same provinces.InterventionConsenting participants are allocated via central randomisation to bedtime vs morning use of all antihypertensives.Follow-up(1) Telephone or email questionnaire at 1 week, 6 weeks, 6 months and every 6 months thereafter, and (2) accessing linked governmental healthcare databases tracking hospital and community medical services.Primary outcomeComposite of all-cause death, or hospitalisation for myocardial infarction/acute-coronary syndrome, stroke or congestive heart failure.Secondary outcomesEach primary outcome element on its own, all-cause hospitalisation or emergency department visit, long-term care admission, non-vertebral fracture, new glaucoma diagnosis, 18-month cognitive decline from baseline (via Short Blessed Test).Select other outcomesSelf-reported nocturia burden at 6 weeks and 6 months (no, minor or major burden), 1-year self-reported overall health score (EQ-5D-5L), self-reported falls, total cost of care (acute and community over study duration) and mean sleep-time systolic blood pressure after 6 months (via 24-hour monitor in a subset of 302 sequential participants).Primary outcome analysisCox proportional hazards survival analysis.Sample sizeThe trial will continue until a projected 254 primary outcome events have occurred.Current statusEnrolment ongoing (3227 randomised to date).

Ethics and dissemination: BedMed has ethics approval from six research ethics review boards and will publish results in a peer-reviewed journal.

Trial registration number: NCT02990663.

Keywords: cardiology; clinical pharmacology; clinical trials; hypertension; primary care.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Veerman DP, Imholz BP, Wieling W, et al. . Circadian profile of systemic hemodynamics. Hypertension 1995;26:55–9. 10.1161/01.HYP.26.1.55
    1. Clement DL, De Buyzere ML, De Bacquer DA, et al. . Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407–15. 10.1056/NEJMoa022273
    1. Verdecchia P, Porcellati C, Schillaci G, et al. . Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994;24:793–801. 10.1161/01.HYP.24.6.793
    1. Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. . Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension 2007;49:1235–41. 10.1161/HYPERTENSIONAHA.107.087262
    1. Fagard RH, Celis H, Thijs L, et al. . Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008;51:55–61. 10.1161/HYPERTENSIONAHA.107.100727
    1. Hermida RC, Ayala DE, Fernández JR, et al. . Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013;30:280–314. 10.3109/07420528.2012.709448
    1. Hermida RC, Ayala DE, Mojón A, et al. . Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27:1629–51. 10.3109/07420528.2010.510230
    1. Nerenberg KA, Zarnke KB, Leung AA, et al. . Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol 2018;34:506–25. 10.1016/j.cjca.2018.02.022
    1. Unger T, Borghi C, Charchar F, et al. . 2020 International Society of hypertension global hypertension practice guidelines. Hypertension 2020;75:1334–57. 10.1161/HYPERTENSIONAHA.120.15026
    1. Whelton PK, Carey RM, Aronow WS, et al. . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American heart association Task force on clinical practice guidelines. Hypertension 2018;71:e13–115. 10.1161/HYP.0000000000000065
    1. NICE Guidelines . Hypertension in adults: diagnosis and management. Available: [Accessed 13 Dec 2021].
    1. Burnier M, Kreutz R, Narkiewicz K, et al. . Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning? J Hypertens 2020;38:1396–406. 10.1097/HJH.0000000000002532
    1. Turgeon RD, Althouse AD, Cohen JB, et al. . Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications: Controversies in Hypertension - Con Side of the Argument. Hypertension 2021;78:871–8. 10.1161/HYPERTENSIONAHA.121.16501
    1. Hermida RC, Ayala DE, Fernández JR, et al. . Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007;50:715–22. 10.1161/HYPERTENSIONAHA.107.094235
    1. Hermida RC, Ayala DE, Fontao MJ, et al. . Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int 2010;27:560–74. 10.3109/07420528.2010.485411
    1. Hermida RC, Ayala DE, Fontao MJ, et al. . Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiol Int 2010;27:1287–303. 10.3109/07420528.2010.489167
    1. Hermida RC, Ayala DE, Mojón A, et al. . Reduction of morning blood pressure surge after treatment with nifedipine GITS at bedtime, but not upon awakening, in essential hypertension. Blood Press Monit 2009;14:152–9. 10.1097/MBP.0b013e32832e0d80
    1. Hermida RC, Ayala DE, Mojón A, et al. . Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008;25:950–70. 10.1080/07420520802544589
    1. Hermida RC, Ayala DE, Mojón A, et al. . Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens 2008;21:948–54. 10.1038/ajh.2008.216
    1. Hermida RC, Ayala DE, Mojón A, et al. . Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens 2009;22:896–903. 10.1038/ajh.2009.83
    1. Hermida RC, Ayala DE, Chayan L, et al. . Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009;26:61–79. 10.1080/07420520802548135
    1. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. . Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial. Eur Heart J 2020;41:4565–76. 10.1093/eurheartj/ehz754
    1. Kreutz R, Kjeldsen SE, Burnier M, et al. . Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. J Hypertens 2020;38:2144–5. 10.1097/HJH.0000000000002671
    1. Brunström M, Kjeldsen SE, Kreutz R, et al. . Missing verification of source data in hypertension research: the HYGIA project in perspective. Hypertension 2021;78:555–8. 10.1161/HYPERTENSIONAHA.121.17356
    1. Carlsberg B, Brunstrom B. Is bedtime the best time of day? International Society of hypertension March 2020 Newsletter. Available: [Accessed 17 Dec 2021].
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (probe) study. A novel design for intervention trials. prospective randomized open blinded end-point. Blood Press 1992;1:113–9. 10.3109/08037059209077502
    1. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthalmol 2005;16:79–83. 10.1097/01.icu.0000156134.38495.0b
    1. Hayreh SS. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. Curr Opin Ophthalmol 1999;10:474–82. 10.1097/00055735-199912000-00017
    1. Hayreh SS, Zimmerman MB, Podhajsky P, et al. . Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994;117:603–24. 10.1016/S0002-9394(14)70067-4
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International classification of diseases, revisions 9 and 10. Stroke 2005;36:1776–81. 10.1161/01.STR.0000174293.17959.a1
    1. Quan H, Sundararajan V, Halfon P, et al. . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–9. 10.1097/01.mlr.0000182534.19832.83
    1. Tonelli M, Wiebe N, Fortin M, et al. . Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inform Decis Mak 2016;15:31. 10.1186/s12911-015-0155-5
    1. WebMD . Diuretics (water pills) for high blood pressure. Available: [Accessed 1 Jul 2021].
    1. Heart and Stroke Foundation of Canada . Diuretics. Available: [Accessed 1 Jul 2021].
    1. Maasland L, van Oostenbrugge RJ, Franke CF, et al. . Patients enrolled in large randomized clinical trials of antiplatelet treatment for prevention after transient ischemic attack or ischemic stroke are not representative of patients in clinical practice. Stroke 2009;40:2662–8. 10.1161/STROKEAHA.109.551812
    1. Masoudi FA, Havranek EP, Wolfe P, et al. . Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003;146:250–7. 10.1016/S0002-8703(03)00189-3
    1. Ruokoniemi P, Sund R, Arffman M, et al. . Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. BMJ Open 2014;4:e005402. 10.1136/bmjopen-2014-005402
    1. Travers J, Marsh S, Williams M, et al. . External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62:219–23. 10.1136/thx.2006.066837
    1. Travers J, Marsh S, Caldwell B, et al. . External validity of randomized controlled trials in COPD. Respir Med 2007;101:1313–20. 10.1016/j.rmed.2006.10.011
    1. Mueller PS, Montori VM, Bassler D, et al. . Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med 2007;146:878–81. 10.7326/0003-4819-146-12-200706190-00009
    1. Rorie DA, Rogers A, Mackenzie IS, et al. . Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the treatment in morning versus evening (TIME) study. BMJ Open 2016;6:e010313. 10.1136/bmjopen-2015-010313
    1. Garrison SR. BedMed-Frail: does the potential benefit of bedtime antihypertensive prescribing extend to frail populations? National Institutes of health clinical trials registry. Available: [Accessed 12 Jan 2021].

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться